Glucotrack Subsidiary Advances Single-Injection Administration Strategy
Lokahi Therapeutics completed a nonclinical study supporting a shift from 15 injections to a single subcutaneous injection, with regulatory discussions encouraging an accelerated clinical timeline for 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day